Menu

NCI Gets Personal

The National Cancer Institute is launching a Phase 2 trial matching patients with specific mutations to drugs tailored to those genetic changes.

Jun 2, 2015
Bob Grant

IMAGE, NCI - DANIEL SONECommencing a study that will enroll 1,000 cancer patients with specific tumor mutations, researchers at the National Cancer Institute (NCI) will be matching participants to more than 20 different drugs, each designed to target specific genetic changes. The NCI team announced the launch of its Molecular Analysis for Therapy Choice (NCI-MATCH) trial yesterday (June 1) at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. “This is the largest and most rigorous precision oncology trial that has ever been attempted,” James Doroshow, deputy director of the NCI, said at the ASCO meeting.

Precision medicine, sometimes referred to as personalized medicine, is an increasingly prevalent approach, championed by President Barack Obama in his 2015 State of the Union address. Researchers will begin screening and enrolling patients in the Phase 2 NCI-MATCH trial at 2,400 US clinical sites next month. Doroshow said at the briefing announcing the launch of the study that he expects it to cost $30 million to $40 million, though the price tag may change as the trial progresses.

Cancer researchers are hopeful that the NCI-MATCH trial and ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, which was also announced Monday, will advance precision medicine and increase scientists’ understanding of basic cancer biology. “That’s the promise of precision medicine,” José Baselga of New York City’s Memorial Sloan Kettering Cancer Center told The Washington Post. “You [now] have the capability to identify what’s driving the particular tumor and then to devise methodologies that result in a better understanding of the disease and the development of better therapies. That’s where the optimism resides.”

Ten pharmaceutical companies are providing more than 20 drugs—some that are currently on the market and others that are still in development—to be used in the NCI-MATCH trial. These include Pfizer’s crizotinib (Xalkori), which functions as a protein kinase inhibitor, and GSK’s trametinib (Mekinist), a mitogen-activated protein kinase kinase (MEK) inhibitor.

The smaller TAPUR trial, which will begin enrolling patients by the end of the year, is designed to test already approved drugs targeted to specific mutations, but in tumors located in tissues other than those in the compounds’ original indications.

“These are trials that are an acknowledgment that we are in the midst of the era of precision medicine,” Sandra Horning, chief medical officer and head of global product development at Roche—which is providing drugs for the trials—told The Wall Street Journal. “It will be a great way to learn where targeted therapies might have utility that we don’t understand.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.